Identification of Serotonin 5-HT3 Recognition Sites in Membranes of N1E-115 Neuroblastoma Cells by Radioligand Binding
Overview
Pharmacology
Affiliations
[3H]ICS 205-930 recognition sites were analyzed in membranes prepared from murine neuroblastoma N1E-115 cells. [3H]ICS 205-930 bound rapidly, reversibly, and stereoselectively to a homogeneous population of high affinity recognition sites: Bmax = 40 +/- 5 fmol/mg of protein, pKD = 9.20 +/- 0.05 (n = 11). Nonlinear regression and Scatchard analysis of saturation data suggested the existence of a single class of [3H]ICS 205-930 recognition sites on N1E-115 cells. The affinity of [3H]ICS 205-930 determined in kinetic studies was in agreement with that obtained under equilibrium conditions. Competition studies carried out with a large variety of agonists and antagonists also suggested the presence of a homogeneous population of [3H]ICS 205-930 recognition sites. [3H]ICS 205-930-binding sites displayed the pharmacological profile of a 5-HT3 receptor. Potent 5-HT3 receptor antagonists showed nM affinities for [3H]ICS 205-930-binding sites with the following rank order of potency: SDZ 206-830 greater than SDZ 206-792 greater than ICS 205-930 greater than BRL 43694 greater than quipazine greater than BRL 24924 greater than MDL 72222 greater than GR 38032F. Methiothepine, mCPP, and metoclopramide showed sub-microM affinity. The rank order of potency of agonists was: 5-HT greater than phenylbiguanide = 2-methyl-5-HT much greater than 5-methoxytryptamine = 5-carboxamidotryptamine. All antagonist competition curves were steep (pseudo-Hill coefficients not lower than 1), monophasic, and best fit for a one-site model; 5-HT and 2-methyl-5-HT produced pseudo-Hill coefficients of 1.2-1.4. Drugs acting at 5-HT1, 5-HT2, alpha- and beta-adrenergic, dopaminergic, and histaminergic receptors (methysergide, ketanserin, propranolol, phentolamine, sulpiride, SCH 23390, cimetidine) were essentially inactive at 10 mumol/liter. The binding of [3H]ICS 205-930 was not affected by guanine and adenine nucleotides (GTP, GppNHp, and ATP) at 1 mmol/liter. These nucleotides did not affect the binding of agonists, suggesting that 5-HT3 recognition sites are not coupled to G-proteins. The interactions of agonists and antagonists with [3H]ICS 205-930 recognition sites were competitive in nature, as demonstrated by saturation experiments carried out with [3H]ICS 205-930 in the presence and the absence of unlabeled compounds: apparent Bmax values were not reduced, whereas apparent KD values were increased in the presence of competing ligands.(ABSTRACT TRUNCATED AT 400 WORDS)
Hydrophobic photolabeling studies identify the lipid-protein interface of the 5-HT3A receptor.
Sanghvi M, Hamouda A, Davis M, Morton R, Srivastava S, Pandhare A Biochemistry. 2009; 48(39):9278-86.
PMID: 19715355 PMC: 2778300. DOI: 10.1021/bi901208j.
Influence of sodium substitutes on 5-HT-mediated effects at mouse 5-HT3 receptors.
Barann M, Schmidt K, Gothert M, Urban B, Bonisch H Br J Pharmacol. 2004; 142(3):501-8.
PMID: 15148263 PMC: 1574959. DOI: 10.1038/sj.bjp.0705788.
Selection of distinct conformational states of the 5-HT3 receptor by full and partial agonists.
van Hooft J, Vijverberg H Br J Pharmacol. 1996; 117(5):839-46.
PMID: 8851499 PMC: 1909396. DOI: 10.1111/j.1476-5381.1996.tb15269.x.
Evaluation of phenylpiperazines as targeting agents for neuroblastoma.
Babich J, GRAHAM W, Fischman A Br J Cancer. 1996; 74(6):917-24.
PMID: 8826858 PMC: 2074721. DOI: 10.1038/bjc.1996.457.
SDZ PSD 958, a novel D1 receptor antagonist with potential limbic selectivity.
Markstein R, Gull P, Rudeberg C, Urwyler S, Jaton A, McAllister K J Neural Transm (Vienna). 1996; 103(3):261-76.
PMID: 8739838 DOI: 10.1007/BF01271238.